Zonovate is a drug that contains alfaturoctocogue, a substance produced in the laboratory that has an action similar to the coagulation factor VIII, which is lacking in people with hemophilia A and who is responsible for coagulation, preventing excessive bleeding.
This medicine is used in the form of an injection and does not contain any animal or human component in its constitution and is made completely in the laboratory. It has already been approved by Anvisa in Brazil and, therefore, should be distributed by hospitals.
What is it for
Zonovate with alfaturoctocog is indicated to prevent bleeding or treat bleeding in people with hemophilia A, of any age.
This injection can be found in several different doses which include 250, 500, 1000, 1500, 2000 or 3000 IU, depending on the treatment needs.
How to use
The administration of Zonovate should always be done in the hospital by a health professional, such as the doctor or nurse, as it is necessary that the injection be made directly into the vein. The dose of medicament is calculated by the physician according to the purpose of the treatment but usually are:
- Prevention of bleeding : 20 to 50 IU per kg of body weight, every 2 or 3 days;
- Treatment of bleeding : The dose should be calculated according to the severity of the bleeding.
In children and adolescents, it is usually recommended to take larger doses of the medication or to take the treatment at shorter intervals.
Possible side effects
The most common side effects of using substances such as alfaturoctocogue include redness at the injection site, feeling of excessive tiredness, headache, dizziness, insomnia, increased heart rate, increased blood pressure, fever, muscle aches, swelling of the arms and legs or frequent appearance of purple spots.
Who should not take
Zonovate is contraindicated for people who are allergic to any of the ingredients in the formula. In pregnant and lactating women, it should be used only with the advice of a physician.
